PRTN3 and rheumatoid arthritis: Studies have suggested that the presence of anti-cyclic citrullinated peptide antibodies (ACPA) may be associated with superior responses to rituximab, adalimumab, and abatacept [11, 12], but also increased mortality [13], and may mark an indication for more intense RA treatment with csDMARDs and glucocorticoids [14].